PREDICTION OF TREATMENT EFFICIENCY IN PATIENTS WITH THE OVARIAN CANCER
DOI:
https://doi.org/10.11603/24116-4944.2017.2.8043Keywords:
ovarian cancer, treatment, resistance to platinum, prognosis, platinum, disregulator violations, sanogenesis.Abstract
The aim of study – to learn biomedical bases of predicting the effectiveness of platinum chemotherapy and increase the sensitivity of tumors to first-line chemotherapy.
Materials and Methods. From 2007 to 2011 189 patients with ovarian adenocarcinoma III-IV stage were examined. They underwent adjuvant chemotherapy courses with drugs platinum after suboptimal or suboptimal cytoreductive surgery in postoperative period. The criterion for the dividing into groups was sensitivity to platinum drugs.
Results and Discussion. It was shown that women with ovarian cancer have typical tension of sanogenetic mechanisms in human body. State of sanogenesis in patients with ovarian cancer affects the sensitivity or refractority of tumors to chemotherapy with platinum drugs. To the markers of platinum-resistance we should include the genetic ones (presence of mutions in BRCA1 5832insC and BRCA2 6174delAG in hetero- and homozygous variant, microsatellite instability), high activity of cyclins D and E, increased levels of catecholamines, high level expression of nitric oxide, the degree hyperuricemia, active expression receptors for epidermal growth factor and activity CAS 20q13. Women with the presence of these factors need to apply appropriate drugs for correction of disregulator violations.
Conclusions. If probable platinumresistance is advisable due to the standard first-line therapy they should use the drugs for correction of disregulator disorders (donors of nitric oxide, detoxicant, anti-uricemic remedies). In patients with predictable sensitivity to platinum standard first-line treatment can be supplemented by remedies that can improve the tolerated therapy, but it is inappropriate to use the medicines for correction of disregulator disorders.
References
Axel, M.A., Barinov, V.V., & Bokina, L.I. (2009). Lektsii po onkoginekologii [Lectures on oncogynecology]. Mosсow: MEDpressinform [in Russian].
Bohman, Ya.V. (2007). Lektsii po onkoginekologii [Lectures on oncogynecology]. Moscow: MIA [in Russian].
Vazhenin, A.V., Zharov, A.V., & Shimotkina, I.G. (2010). Aktualnye voprosy klinicheskoy onkoginekologii [Actual questions of clinical oncogynecology]. Mosсow: STROM [in Russian].
Zaporozhyan, V.M. (Ed.) (2004). Henetyka pukhlyn zhinochyh reproduktivnykh orhanіv [Genetics of the femalereproductive organs]. Odesa derzh. med. un-t [in Ukrainian].
Zaporozhan, V.N., Kordyum, V.A., & Bazhora, Y. (Ed. Zaporozhyan, V.N.) (2008). Geneticheskaya meditsyna [Genetic medicine]. Odesa: ONMEDU [in Ukrainian].
Dubinina, V.G., Rybin, A.I., Lukyanchuk, O.V., & Kuznetsova, O.V. (2013). Analiz mutatsii geniv BRCA-1 i BRCA-2 u platynorefrakternyh patsientok z rakom yaichnikov [Analysis of mutation of BRCA-1 and BRCA-2 genes in platinum-refractory patients with ovarian cancer]. News of Naval Medicine, 1, 46-52 [in Russian].
Dubinina, V.G., Rybin, A.I., Kuznetsova, O.V., & Morozyuk, O.N. (2015). Aktivnost belka p53 u bolnykh z rakom yaichnikov v zavisimosti ot chuvstvitelnosti k preparatam platiny. [Activity of p53 protein in patients with ovarian cancer, depending on sensitivity to platinum preparations]. Klinichna onkolohiia – Clinical oncology, 4, 1-4 [in Russian].
Buchinska, L.G., Grinkevich, V.M., Yurchenko, N.P. (2009). Ekspressia of p53, VEGF i CD34 v tkani opuholi i vyzhivaemost bolnykh seroznym rakom yaichnikov [Expression of p53, VEGF and CD34 in tumor tissues and survilance of patients with the serous ovarian cancer]. Onkolohiia – Oncology, (11), 2, p. 109-112 [in Russian].
Kozachenko, V. P. (Ed). (2005). Klinicheskaya onkoginekologia [Clinical oncogynecology]. Moscow: Meditsina [in Russian].
Philip, J., Dysay, & William, T. Krisman (2011). Klinicheskaya onkoginekologia: v 3 tomakh [Clinical oncogynecology: in 3 volumes]. Moscow: Prakticheskaya meditsyna [in Russian].
Кolesnik, O.O. (Ed). Fedorenko, Z.P., Mykhailovych, Yu.Y., Hulak L.O. (2016). Rak v Ukraini, 2014-2015. Zakhvoriuvanist, smertnist, pokaznyki diialnosti onkolohichnoi sluzhby [Cancer in Ukraine, 2014-2015. Morbidity, mortality, the indeces of oncological service activity]. Кyiv [in Ukrainian].
Svintsitskyy, V.S. (2015). Seroznyi rak yaichnikov:testirovanie mutatsyy genov BRCA1 and BRCA2 v Ukraini
[Serous ovarian cancer: testing of mutations in the BRCA1 and BRCA2 genes in Ukraine]. Eurasian oncology journal (attachment), 79-82 [in Russian].
Urmancheeva, A.F., Tyulyandina, S.A., & Moiseenko, V.M. (2008). Prakticheskaya onkoginekologia; izbrannye lektsii [Practical oncogynecology: selected lectures]. St.-Petersburg: "TOMM" [in Russian].
Chu, E., & De Vita, V.T. (Ed.) (2008). Khimioterapia zlokachestvennyh opuholei [Chemotherapy of malignant
neoplasms] / (translated from English). Moscow: Practice [in Russian].
Ambudakar, S.V., Dey, S., & Hrycyna, C.A. (1999). Biochemical, cellular and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. (39), 361-398.16. Chu, G. (2004). Cellular responses to cisplatin. J. Biol. Chem. (2269), 787-790.
Lynch, H.T., Casey, M.J., & Snyder C.L. (2009). Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol. Oncol. 3, 97-137.
Rybin, A. I. (2016). Personalized managing of the patients with serous ovarian cancer. ESGO Prevention in gynecological malignancies, 08-10, Antalya, Turkey. 35 p.
Shulman, L.P., & Dungan, J.S. (2010). Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer. Cancer Treat Res., 156, 69-85.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
